GenFleet broadens its RAS ambitions
And Treeline and HengRui also get in on the pan-RAS act.
Pfizer makes haste to go EZ
The company sticks with EZH2, despite others adding EZH1 inhibition.
And Treeline and HengRui also get in on the pan-RAS act.
The company sticks with EZH2, despite others adding EZH1 inhibition.
